Items where authors include "Allum, WH"

Article

Muti, HS, Heij, LR, Keller, G et al. (32 more authors) (2021) Development and validation of deep learning classifiers to detect Epstein-Barr virus and microsatellite instability status in gastric cancer: a retrospective multicentre cohort study. The Lancet Digital Health, 3 (10). e654-e664. ISSN 2589-7500

Davarzani, N, Hewitt, LC, Hale, MD et al. (8 more authors) (2020) Histological intratumoral heterogeneity in pretreatment esophageal cancer biopsies predicts survival benefit from neoadjuvant chemotherapy: results from the UK MRC OE02 trial. Diseases of the Esophagus, 33 (8). doaa058. ISSN 1120-8694

Sundar, R, Ng, A, Zouridis, H et al. (18 more authors) (2019) DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial. European Journal of Cancer, 123. pp. 48-57. ISSN 0959-8049

Allum, WH, Smyth, EC, Blazeby, JM et al. (6 more authors) (2019) Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro‐oesophageal junction. British Journal of Surgery, 106 (9). pp. 1204-1215. ISSN 0007-1323

Davarzani, N, Hutchins, GGA orcid.org/0000-0002-1707-4415, West, NP orcid.org/0000-0002-0346-6709 et al. (8 more authors) (2018) Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy – results from the MRC OE02 oesophageal cancer trial. Histopathology, 72 (7). pp. 1180-1188. ISSN 0309-0167

Cunningham, D, Stenning, SP, Smyth, EC et al. (15 more authors) (2017) Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial. Lancet Oncology, 18 (3). pp. 357-370. ISSN 1470-2045

Hale, MD, Nankivell, M, Hutchins, GG et al. (11 more authors) (2016) Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma –results from the UK MRC OE02 trial. Oncotarget, 7 (47). pp. 77565-77575. ISSN 1949-2553

Smyth, EC, Fassan, M, Cunningham, D et al. (13 more authors) (2016) Effect of pathologic tumor response and nodal status on survival in the medical research council adjuvant gastric infusional chemotherapy trial. Journal of Clinical Oncology, 34 (23). pp. 2721-2727. ISSN 0732-183X

Proceedings Paper

Athauda, A, Nankivell, MG, Langley, RE et al. (17 more authors) (2019) Impact of age and sex on chemotherapy (CTx) efficacy, toxicity and survival in early oesophagogastric (OG) cancer: A pooled analysis of 3265 patients from four large randomised trials (OE02, OE05, MAGIC & ST03). In: Journal of Clinical Oncology. Annual Meeting of the American Society of Clinical Oncology (ASCO), 31 May - 04 Jun 2019, Chicago, IL, USA. American Society of Clinical Oncology (ASCO) .

Hutchins, GGA orcid.org/0000-0002-1707-4415, Davarzani, N, West, NP orcid.org/0000-0002-0346-6709 et al. (8 more authors) (2018) Defining the Clinical Value of Pathological Lymph Node Status and Primary Tumour Regression Grading Following Neoadjuvant Therapy in Oesophageal Cancer: Results from the MRC OE02 Trial. In: Journal of Pathology. Maastricht Pathology 2018: 11th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 19-22 Jun 2018, Maastricht, the Netherlands. Wiley , S16-S16.